Dopamine

Structure

A dopamine molecule consists of a catechol structure (a benzene ring with two hydroxyl side groups) with one amine group attached via an ethyl chain. As such, dopamine is the simplest possible catecholamine, a family that also includes the neurotransmitters norepinephrine and epinephrine. The presence of a benzene ring with this amine attachment makes it a substituted phenethylamine, a family that includes numerous psychoactive drugs.

Like most amines, dopamine is an organic base. As a base, it is generally protonated in acidic environments (in an acid-base reaction).

Biochemistry

Synthesis

Dopamine is synthesized in a restricted set of cell types, mainly neurons and cells in the medulla of the adrenal glands. The primary and minor metabolic pathways respectively are:

:Primary: L-Phenylalanine → L-Tyrosine → L-DOPA → Dopamine :Minor: L-Phenylalanine → L-Tyrosine → p-Tyramine → Dopamine :Minor: L-Phenylalanine → m-Tyrosine → m-Tyramine → Dopamine

The direct precursor of dopamine, L-DOPA, can be synthesized indirectly from the essential amino acid phenylalanine or directly from the non-essential amino acid tyrosine. These amino acids are found in nearly every protein and so are readily available in food, with tyrosine being the most common. Although dopamine is also found in many types of food, it is incapable of crossing the blood–brain barrier that surrounds and protects the brain. It must therefore be synthesized inside the brain to perform its neuronal activity.

L-Phenylalanine is converted into L-tyrosine by the enzyme phenylalanine hydroxylase, with molecular oxygen (O2) and tetrahydrobiopterin as cofactors. L-Tyrosine is converted into L-DOPA by the enzyme tyrosine hydroxylase, with tetrahydrobiopterin, O2, and iron (Fe2+) as cofactors. L-DOPA is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase (also known as DOPA decarboxylase), with pyridoxal phosphate as the cofactor.

Dopamine itself is used as precursor in the synthesis of the neurotransmitters norepinephrine and epinephrine. Dopamine is converted into norepinephrine by the enzyme dopamine β-hydroxylase, with O2 and L-ascorbic acid as cofactors. Norepinephrine is converted into epinephrine by the enzyme phenylethanolamine N-methyltransferase with S-adenosyl-L-methionine as the cofactor.

Some of the cofactors also require their own synthesis. Deficiency in any required amino acid or cofactor can impair the synthesis of dopamine, norepinephrine, and epinephrine.

Degradation

Dopamine is broken down into inactive metabolites by a set of enzymes—monoamine oxidase (MAO), catechol-O-methyl transferase (COMT), and aldehyde dehydrogenase (ALDH), acting in sequence. Both isoforms of monoamine oxidase, MAO-A and MAO-B, effectively metabolize dopamine.

• Dopamine → DOPAL → DOPAC → HVA – catalyzed by MAO, ALDH, and COMT respectively
• Dopamine → 3-Methoxytyramine → HVA – catalyzed by COMT and MAO+ALDH respectively

In clinical research on schizophrenia, measurements of homovanillic acid in plasma have been used to estimate levels of dopamine activity in the brain. A difficulty in this approach however, is separating the high level of plasma homovanillic acid contributed by the metabolism of norepinephrine.

Although dopamine is normally broken down by an oxidoreductase enzyme, it is also susceptible to oxidation by direct reaction with oxygen, yielding quinones plus various free radicals as products. The rate of oxidation can be increased by the presence of ferric iron or other factors. Quinones and free radicals produced by autoxidation of dopamine can poison cells, and there is evidence that this mechanism may contribute to the cell loss that occurs in Parkinson's disease and other conditions.

Functions

Cellular effects

Main article: Dopamine receptor, TAAR1

Dopamine exerts its effects by binding to and activating cell surface receptors. All of them function as metabotropic, G protein-coupled receptors, meaning that they exert their effects via a complex second messenger system. These receptors can be divided into two families, known as D1-like and D2-like. For receptors located on neurons in the nervous system, the ultimate effect of D1-like activation (D1 and D5) can be excitation (via opening of sodium channels) or inhibition (via opening of potassium channels); the ultimate effect of D2-like activation (D2, D3, and D4) is usually inhibition of the target neuron. Consequently, it is incorrect to describe dopamine itself as either excitatory or inhibitory: its effect on a target neuron depends on which types of receptors are present on the membrane of that neuron and on the internal responses of that neuron to the second messenger cAMP. D1 receptors are the most numerous dopamine receptors in the human nervous system; D2 receptors are next; D3, D4, and D5 receptors are present at significantly lower levels.

Storage, release, and reuptake

Inside the brain, dopamine functions as a neurotransmitter and neuromodulator, and is controlled by a set of mechanisms common to all monoamine neurotransmitters. Dopamine is stored in these vesicles until it is ejected into the synaptic cleft. In most cases, the release of dopamine occurs through a process called exocytosis which is caused by action potentials, but it can also be caused by the activity of an intracellular trace amine-associated receptor, TAAR1. TAAR1 is a high-affinity receptor for dopamine, trace amines, and certain substituted amphetamines that is located along membranes in the intracellular milieu of the presynaptic cell; activation of the receptor can regulate dopamine signaling by inducing dopamine reuptake inhibition and efflux as well as by inhibiting neuronal firing through a diverse set of mechanisms.

Once in the synapse, dopamine binds to and activates dopamine receptors. These can be postsynaptic dopamine receptors, which are located on dendrites (the postsynaptic neuron), or presynaptic autoreceptors (e.g., the D2sh and presynaptic D3 receptors), which are located on the membrane of an axon terminal (the presynaptic neuron). After the postsynaptic neuron elicits an action potential, dopamine molecules quickly become unbound from their receptors. They are then absorbed back into the presynaptic cell, via reuptake mediated either by the dopamine transporter or by the plasma membrane monoamine transporter. Once back in the cytosol, dopamine can either be broken down by a monoamine oxidase or repackaged into vesicles by VMAT2, making it available for future release.

In the brain the level of extracellular dopamine is modulated by two mechanisms: phasic and tonic transmission. Phasic dopamine release, like most neurotransmitter release in the nervous system, is driven directly by action potentials in the dopamine-containing cells. Tonic dopamine transmission occurs when small amounts of dopamine are released without being preceded by presynaptic action potentials. Tonic transmission is regulated by a variety of factors, including the activity of other neurons and neurotransmitter reuptake.

{{Anchor|Functions in the brain}} Central nervous system

Main article: Dopaminergic cell groups, Dopaminergic pathways

Inside the brain, dopamine plays important roles in executive functions, motor control, motivation, arousal, reinforcement, and reward, as well as lower-level functions including lactation, sexual gratification, and nausea. The dopaminergic cell groups and pathways make up the dopamine system which is neuromodulatory.

Dopaminergic neurons (dopamine-producing nerve cells) are comparatively few in number—a total of around 400,000 in the human brain—and their cell bodies are confined in groups to a few relatively small brain areas. In their scheme, areas A1 through A7 contain the neurotransmitter norepinephrine, whereas A8 through A14 contain dopamine. The dopaminergic areas they identified are the substantia nigra (groups 8 and 9); the ventral tegmental area (group 10); the posterior hypothalamus (group 11); the arcuate nucleus (group 12); the zona incerta (group 13) and the periventricular nucleus (group 14).

The substantia nigra is a small midbrain area that forms a component of the basal ganglia. This has two parts—an input area called the pars reticulata and an output area called the pars compacta. The dopaminergic neurons are found mainly in the pars compacta (cell group A8) and nearby (group A9). In humans, the projection of dopaminergic neurons from the substantia nigra pars compacta to the dorsal striatum, termed the nigrostriatal pathway, plays a significant role in the control of motor function and in learning new motor skills. These neurons are especially vulnerable to damage, and when a large number of them die, the result is a parkinsonian syndrome.

The ventral tegmental area (VTA) is another midbrain area. The most prominent group of VTA dopaminergic neurons projects to the prefrontal cortex via the mesocortical pathway and another smaller group projects to the nucleus accumbens via the mesolimbic pathway. Together, these two pathways are collectively termed the mesocorticolimbic projection. Mesocorticolimbic neurons play a central role in reward and other aspects of motivation. Accumulating literature shows that dopamine also plays a crucial role in aversive learning through its effects on a number of brain regions.

The posterior hypothalamus has dopamine neurons that project to the spinal cord, but their function is not well established.

The arcuate nucleus and the periventricular nucleus of the hypothalamus have dopamine neurons that form an important projection—the tuberoinfundibular pathway which goes to the pituitary gland, where it influences the secretion of the hormone prolactin.

The zona incerta, grouped between the arcuate and periventricular nuclei, projects to several areas of the hypothalamus, and participates in the control of gonadotropin-releasing hormone, which is necessary to activate the development of the male and female reproductive systems, following puberty.

An additional group of dopamine-secreting neurons is found in the retina of the eye.

Basal ganglia

The largest and most important sources of dopamine in the vertebrate brain are the substantia nigra and ventral tegmental area. The substantia nigra sends a dopaminergic projection to the dorsal striatum, while the ventral tegmental area sends a similar type of dopaminergic projection to the ventral striatum.

Progress in understanding the functions of the basal ganglia has been slow. The most popular hypotheses, broadly stated, propose that the basal ganglia play a central role in action selection. The action selection theory in its simplest form proposes that when a person or animal is in a situation where several behaviors are possible, activity in the basal ganglia determines which of them is executed, by releasing that response from inhibition while continuing to inhibit other motor systems that if activated would generate competing behaviors. Thus the basal ganglia, in this concept, are responsible for initiating behaviors, but not for determining the details of how they are carried out. In other words, they essentially form a decision-making system.

The basal ganglia can be divided into several sectors, and each is involved in controlling particular types of actions. The ventral sector of the basal ganglia (containing the ventral striatum which receives projections from ventral tegmental area) operates at the highest level of the hierarchy, selecting actions at the whole-organism level. The dorsal sectors (containing the dorsal striatum which receives projections from substantia nigra) operate at lower levels, selecting the specific muscles and movements that are used to implement a given behavior pattern.

Dopamine contributes to the action selection process in at least two important ways. First, it sets the "threshold" for initiating actions.

The second important effect of dopamine is as a "teaching" signal. When an action is followed by an increase in dopamine activity, the basal ganglia circuit is altered in a way that makes the same response easier to evoke when similar situations arise in the future. This is a form of operant conditioning, in which dopamine plays the role of a reward signal.

Reward

In the language used to discuss the reward system, reward is the attractive and motivational property of a stimulus that induces appetitive behavior (also known as approach behavior) and consummatory behavior. The motivational or desirable aspect of rewarding stimuli is reflected by the approach behavior that they induce, whereas the pleasure from intrinsic rewards results from consuming them after acquiring them.) corresponds to appetitive or approach behavior while "liking" or pleasure corresponds to consummatory behavior. In human drug addicts, "wanting" becomes dissociated with "liking" as the desire to use an addictive drug increases, while the pleasure obtained from consuming it decreases due to drug tolerance.

Within the brain, dopamine functions partly as a global reward signal. An initial dopamine response to a rewarding stimulus encodes information about the salience, value, and context of a reward. rewards that are expected do not produce a second phasic dopamine response in certain dopaminergic cells, but rewards that are unexpected, or greater than expected, produce a short-lasting increase in synaptic dopamine, whereas the omission of an expected reward actually causes dopamine release to drop below its background level. The "prediction error" hypothesis has drawn particular interest from computational neuroscientists, because an influential computational-learning method known as temporal difference learning makes heavy use of a signal that encodes prediction error. This confluence of theory and data has led to a fertile interaction between neuroscientists and computer scientists interested in machine learning.

Evidence from microelectrode recordings from the brains of animals shows that dopamine neurons in the ventral tegmental area (VTA) and substantia nigra are strongly activated by a wide variety of rewarding events. These reward-responsive dopamine neurons in the VTA and substantia nigra are crucial for reward-related cognition and serve as the central component of the reward system. The function of dopamine varies in each axonal projection from the VTA and substantia nigra; for example, the VTA–nucleus accumbens shell projection assigns incentive salience ("want") to rewarding stimuli and its associated cues, the VTA–prefrontal cortex projection updates the value of different goals in accordance with their incentive salience, the VTA–amygdala and VTA–hippocampus projections mediate the consolidation of reward-related memories, and both the VTA–nucleus accumbens core and substantia nigra–dorsal striatum pathways are involved in learning motor responses that facilitate the acquisition of rewarding stimuli. Some activity within the VTA dopaminergic projections appears to be associated with reward prediction as well.

Pleasure

While dopamine has a central role in causing "wanting," associated with the appetitive or approach behavioral responses to rewarding stimuli, detailed studies have shown that dopamine cannot simply be equated with hedonic "liking" or pleasure, as reflected in the consummatory behavioral response. For example, direct electrical stimulation of dopamine pathways, using electrodes implanted in the brain, is experienced as pleasurable, and many types of animals are willing to work to obtain it. Many types of pleasurable experiences—such as sexual intercourse, eating, and playing video games—increase dopamine release. All addictive drugs directly or indirectly affect dopamine neurotransmission in the nucleus accumbens; However, opiate drugs such as heroin and morphine produce increases in expressions of "liking" and "wanting" behaviors.

A clinical study from January 2019 that assessed the effect of a dopamine precursor (levodopa), dopamine antagonist (risperidone), and a placebo on reward responses to music – including the degree of pleasure experienced during musical chills, as measured by changes in electrodermal activity as well as subjective ratings – found that the manipulation of dopamine neurotransmission bidirectionally regulates pleasure cognition (specifically, the hedonic impact of music) in human subjects. This research demonstrated that increased dopamine neurotransmission acts as a sine qua non condition for pleasurable hedonic reactions to music in humans.

A study published in Nature in 1998 found evidence that playing video games releases dopamine in the human striatum. This dopamine is associated with learning, behavior reinforcement, attention, and sensorimotor integration. Researchers used positron emission tomography scans and 11C-labelled raclopride to track dopamine levels in the brain during goal-directed motor tasks and found that dopamine release was positively correlated with task performance and was greatest in the ventral striatum. This was the first study to demonstrate the behavioral conditions under which dopamine is released in humans. It highlights the ability of positron emission tomography to detect neurotransmitter fluxes during changes in behavior. According to research, potentially problematic video game use is related to personality traits such as low self-esteem and low self-efficacy, anxiety, aggression, and clinical symptoms of depression and anxiety disorders. Additionally, the reasons individuals play video games vary and may include coping, socialization, and personal satisfaction. The DSM-5 defines Internet Gaming Disorder as a mental disorder closely related to Gambling Disorder. This has been supported by some researchers but has also caused controversy.

Outside the central nervous system

Dopamine does not cross the blood–brain barrier, so its synthesis and functions in peripheral areas are to a large degree independent of its synthesis and functions in the brain. A substantial amount of dopamine circulates in the bloodstream, but its functions there are not entirely clear. Dopamine is found in blood plasma at levels comparable to those of epinephrine, but in humans, over 95% of the dopamine in the plasma is in the form of dopamine sulfate, a conjugate produced by the enzyme sulfotransferase 1A3/1A4 acting on free dopamine. The bulk of this dopamine sulfate is produced in the mesenteric organs. The production of dopamine sulfate is thought to be a mechanism for detoxifying dopamine that is ingested as food or produced by the digestive process—levels in the plasma typically rise more than fifty-fold after a meal. Dopamine sulfate has no known biological functions and is excreted in urine.

The relatively small quantity of unconjugated dopamine in the bloodstream may be produced by the sympathetic nervous system, the digestive system, or possibly other organs. These responses might be activated by dopamine released from the carotid body under conditions of low oxygen, but whether arterial dopamine receptors perform other biologically useful functions is not known.

Beyond its role in modulating blood flow, there are several peripheral systems in which dopamine circulates within a limited area and performs an exocrine or paracrine function. The peripheral systems in which dopamine plays an important role include the immune system, the kidneys and the pancreas.

Immune system

In the immune system dopamine acts upon receptors present on immune cells, especially lymphocytes. Dopamine can also affect immune cells in the spleen, bone marrow, and circulatory system. In addition, dopamine can be synthesized and released by immune cells themselves.

Kidneys

The renal dopaminergic system is located in the cells of the nephron in the kidney, where all subtypes of dopamine receptors are present. Dopamine is also synthesized there, by tubule cells, and discharged into the tubular fluid. Its actions include increasing the blood supply to the kidneys, increasing the glomerular filtration rate, and increasing the excretion of sodium in the urine. Hence, defects in renal dopamine function can lead to reduced sodium excretion and consequently result in the development of high blood pressure. There is strong evidence that faults in the production of dopamine or in the receptors can result in a number of pathologies including oxidative stress, edema, and either genetic or essential hypertension. Oxidative stress can itself cause hypertension. Defects in the system can also be caused by genetic factors or high blood pressure.

Pancreas

In the pancreas the role of dopamine is somewhat complex. The pancreas consists of two parts, an exocrine and an endocrine component. The exocrine part synthesizes and secretes digestive enzymes and other substances, including dopamine, into the small intestine.

The pancreatic islets make up the endocrine part of the pancreas, and synthesize and secrete hormones including insulin into the bloodstream. There is evidence that the beta cells in the islets that synthesize insulin contain dopamine receptors, and that dopamine acts to reduce the amount of insulin they release. The source of their dopamine input is not clearly established—it may come from dopamine that circulates in the bloodstream and derives from the sympathetic nervous system, or it may be synthesized locally by other types of pancreatic cells.

Medical uses

Main article: Dopamine (medication)

Dopamine as a manufactured medication is sold under the trade names Intropin, Dopastat, and Revimine, among others. It is on the World Health Organization's List of Essential Medicines. It is most commonly used as a stimulant drug in the treatment of severe low blood pressure, slow heart rate, and cardiac arrest. It is especially important in treating these in newborn infants. It is given intravenously. Since the half-life of dopamine in plasma is very short—approximately one minute in adults, two minutes in newborn infants and up to five minutes in preterm infants—it is usually given in a continuous intravenous drip rather than a single injection.

Its effects, depending on dosage, include an increase in sodium excretion by the kidneys, an increase in urine output, an increase in heart rate, and an increase in blood pressure. Older literature also describes very low doses thought to improve kidney function without other consequences, but recent reviews have concluded that doses at such low levels are not effective and may sometimes be harmful. While some effects result from stimulation of dopamine receptors, the prominent cardiovascular effects result from dopamine acting at α1, β1, and β2 adrenergic receptors as a weak agonist.

Side effects of dopamine include negative effects on kidney function and irregular heartbeats. The LD50, or lethal dose which is expected to prove fatal in 50% of the population, has been found to be: 59 mg/kg (mouse; administered intravenously); 95 mg/kg (mouse; administered intraperitoneally); 163 mg/kg (rat; administered intraperitoneally); 79 mg/kg (dog; administered intravenously).

Disease, disorders, and pharmacology

The dopamine system plays a central role in several significant medical conditions, including Parkinson's disease, attention deficit hyperactivity disorder, Tourette syndrome, schizophrenia, bipolar disorder, and addiction. Aside from dopamine itself, there are many other important drugs that act on dopamine systems in various parts of the brain or body. Some are used for medical or recreational purposes, but neurochemists have also developed a variety of research drugs, some of which bind with high affinity to specific types of dopamine receptors and either agonize or antagonize their effects, and many that affect other aspects of dopamine physiology, including dopamine transporter inhibitors, VMAT inhibitors, and enzyme inhibitors.

Aging brain

Main article: Aging brain

A number of studies have reported an age-related decline in dopamine synthesis and dopamine receptor density (i.e., the number of receptors) in the brain. This decline has been shown to occur in the striatum and extrastriatal regions. Decreases in the D1, D2, and D3 receptors are well documented. The reduction of dopamine with aging is thought to be responsible for many neurological symptoms that increase in frequency with age, such as decreased arm swing and increased rigidity. Changes in dopamine levels may also cause age-related changes in cognitive flexibility.

Multiple sclerosis

Studies reported that dopamine imbalance influences the fatigue in multiple sclerosis. In patients with multiple sclerosis, dopamine inhibits production of IL-17 and IFN-γ by peripheral blood mononuclear cells.

Parkinson's disease

Parkinson's disease is an age-related disorder characterized by movement disorders such as stiffness of the body, slowing of movement, and trembling of limbs when they are not in use. In advanced stages it progresses to dementia and eventually death. These dopamine cells are especially vulnerable to damage, and a variety of insults, including encephalitis (as depicted in the book and movie Awakenings), repeated sports-related concussions, and some forms of chemical poisoning such as MPTP, can lead to substantial cell loss, producing a parkinsonian syndrome that is similar in its main features to Parkinson's disease. Most cases of Parkinson's disease, however, are idiopathic, meaning that the cause of cell death cannot be identified.

The most widely used treatment for parkinsonism is administration of L-DOPA, the metabolic precursor for dopamine. L-DOPA is converted to dopamine in the brain and various parts of the body by the enzyme DOPA decarboxylase. It is often co-administered with an enzyme inhibitor of peripheral decarboxylation such as carbidopa or benserazide, to reduce the amount converted to dopamine in the periphery and thereby increase the amount of L-DOPA that enters the brain. When L-DOPA is administered regularly over a long time period, a variety of unpleasant side effects such as dyskinesia often begin to appear; even so, it is considered the best available long-term treatment option for most cases of Parkinson's disease.

L-DOPA treatment cannot restore the dopamine cells that have been lost, but it causes the remaining cells to produce more dopamine, thereby compensating for the loss to at least some degree. In advanced stages the treatment begins to fail because the cell loss is so severe that the remaining ones cannot produce enough dopamine regardless of L-DOPA levels. Other drugs that enhance dopamine function, such as bromocriptine and pergolide, are also sometimes used to treat Parkinsonism, but in most cases L-DOPA appears to give the best trade-off between positive effects and negative side-effects.

Dopaminergic medications that are used to treat Parkinson's disease are sometimes associated with the development of a dopamine dysregulation syndrome, which involves the overuse of dopaminergic medication and medication-induced compulsive engagement in natural rewards like gambling and sexual activity. The latter behaviors are similar to those observed in individuals with a behavioral addiction.

Drug addiction and psychostimulants

Main article: Addiction

Cocaine, substituted amphetamines (including methamphetamine), Adderall, methylphenidate (marketed as Ritalin or Concerta), and other psychostimulants exert their effects primarily or partly by increasing dopamine levels in the brain by a variety of mechanisms. they non-competitively inhibit dopamine reuptake, resulting in increased dopamine concentrations in the synaptic cleft. Like cocaine, substituted amphetamines and amphetamine also increase the concentration of dopamine in the synaptic cleft, but by different mechanisms.

The effects of psychostimulants include increases in heart rate, body temperature, and sweating; improvements in alertness, attention, and endurance; increases in pleasure produced by rewarding events; but at higher doses agitation, anxiety, or even loss of contact with reality. Drugs in this group can have a high addiction potential, due to their activating effects on the dopamine-mediated reward system in the brain. An important differentiating factor is the onset and duration of action. This rapid and brief action makes its effects easily perceived and consequently gives it high addiction potential. and depending on formulation the effects can last for up to 12 hours. These longer acting formulations have the benefit of reducing the potential for abuse, and improving adherence for treatment by using more convenient dosage regimens.

A variety of addictive drugs produce an increase in reward-related dopamine activity. When people addicted to stimulants go through withdrawal, they do not experience the physical suffering associated with alcohol withdrawal or withdrawal from opiates; instead they experience craving, an intense desire for the drug characterized by irritability, restlessness, and other arousal symptoms, brought about by psychological dependence.

The dopamine system plays a crucial role in several aspects of addiction. At the earliest stage, genetic differences that alter the expression of dopamine receptors in the brain can predict whether a person will find stimulants appealing or aversive. Consumption of stimulants produces increases in brain dopamine levels that last from minutes to hours. Treatment of stimulant addiction is very difficult, because even if consumption ceases, the craving that comes with psychological withdrawal does not.

Psychosis and antipsychotic drugs

Main article: Psychosis

Psychiatrists in the early 1950s discovered that a class of drugs known as typical antipsychotics (also known as major tranquilizers), were often effective at reducing the psychotic symptoms of schizophrenia. This realization led to the so-called dopamine hypothesis of schizophrenia, which postulates that schizophrenia is largely caused by hyperactivity of brain dopamine systems. The dopamine hypothesis drew additional support from the observation that psychotic symptoms were often intensified by dopamine-enhancing stimulants such as methamphetamine, and that these drugs could also produce psychosis in healthy people if taken in large enough doses. These drugs were also used to treat other psychoses. Antipsychotic drugs have a broadly suppressive effect on most types of active behavior, and particularly reduce the delusional and agitated behavior characteristic of overt psychosis.

Later observations, however, have caused the dopamine hypothesis to lose popularity, at least in its simple original form. For one thing, patients with schizophrenia do not typically show measurably increased levels of brain dopamine activity. Even so, many psychiatrists and neuroscientists continue to believe that schizophrenia involves some sort of dopamine system dysfunction. As the "dopamine hypothesis" has evolved over time, however, the sorts of dysfunctions it postulates have tended to become increasingly subtle and complex.

Psychopharmacologist Stephen M. Stahl suggested in a review of 2018 that in many cases of psychosis, including schizophrenia, three interconnected networks based on dopamine, serotonin, and glutamate – each on its own or in various combinations – contributed to an overexcitation of dopamine D2 receptors in the ventral striatum.

Attention deficit hyperactivity disorder

Main article: Attention deficit hyperactivity disorder

Altered dopamine neurotransmission is implicated in attention deficit hyperactivity disorder (ADHD), a condition associated with impaired cognitive control, in turn leading to problems with regulating attention (attentional control), inhibiting behaviors (inhibitory control), and forgetting things or missing details (working memory), among other problems. There are genetic links between dopamine receptors, the dopamine transporter, and ADHD, in addition to links to other neurotransmitter receptors and transporters. The most important relationship between dopamine and ADHD involves the drugs that are used to treat ADHD. The clinical effects of these psychostimulants in treating ADHD are mediated through the indirect activation of dopamine and norepinephrine receptors, specifically dopamine receptor D1 and adrenoceptor α2, in the prefrontal cortex.

Pain

Dopamine plays a role in pain processing in multiple levels of the central nervous system including the spinal cord, periaqueductal gray, thalamus, basal ganglia, and cingulate cortex. Decreased levels of dopamine have been associated with painful symptoms that frequently occur in Parkinson's disease. Abnormalities in dopaminergic neurotransmission also occur in several painful clinical conditions, including burning mouth syndrome, fibromyalgia, and restless legs syndrome.

Nausea

Nausea and vomiting are largely determined by activity in the area postrema in the medulla of the brainstem, in a region known as the chemoreceptor trigger zone. This area contains a large population of type D2 dopamine receptors. In some cases, D2-receptor antagonists such as metoclopramide are useful as anti-nausea drugs.

Fear and anxiety

Simultaneous positron emission tomography (PET) and functional magnetic resonance imaging (fMRI), have shown that the amount of dopamine release is dependent on the strength of conditioned fear response and is linearly coupled to learning-induced activity in the amygdala. Dopamine is generally linked to reward learning, but it also plays a key role in fear learning and extinction by helping to form, store and update fear memories through its interaction with other brain regions like amygdala, ventromedial prefrontal cortex and striatum.

Comparative biology and evolution

Microorganisms

There are no reports of dopamine in archaea, but it has been detected in some types of bacteria and in the protozoan called Tetrahymena. Perhaps more importantly, there are types of bacteria that contain homologs of all the enzymes that animals use to synthesize dopamine.

Animals

Dopamine is used as a neurotransmitter in most multicellular animals. however, dopamine has been reported in the nervous systems of many other radially symmetric species, including the cnidarian jellyfish, hydra and some corals. This dates the emergence of dopamine as a neurotransmitter back to the earliest appearance of the nervous system, over 500 million years ago in the Cambrian Period. Dopamine functions as a neurotransmitter in vertebrates, echinoderms, arthropods, molluscs, and several types of worm.

In every type of animal that has been examined, dopamine has been seen to modify motor behavior. In the model organism, nematode Caenorhabditis elegans, it reduces locomotion and increases food-exploratory movements; in flatworms it produces "screw-like" movements; in leeches it inhibits swimming and promotes crawling. Across a wide range of vertebrates, dopamine has an "activating" effect on behavior-switching and response selection, comparable to its effect in mammals.

Dopamine has also consistently been shown to play a role in reward learning, in all animal groups. For example, dopamine regulates short- and long-term learning in monkeys; in fruit flies, different groups of dopamine neurons mediate reward signals for short- and long-term memories.

It had long been believed that arthropods were an exception to this with dopamine being seen as having an adverse effect. Reward was seen to be mediated instead by octopamine, a neurotransmitter closely related to norepinephrine. Dopamine can also be found in cephalopod ink.

Plants

Many plants, including a variety of food plants, synthesize dopamine to varying degrees. The dopamine in plants is synthesized from the amino acid tyrosine, by biochemical mechanisms similar to those that animals use. It can be metabolized in a variety of ways, producing melanin and a variety of alkaloids as byproducts. The functions of plant catecholamines have not been clearly established, but there is evidence that they play a role in the response to stressors such as bacterial infection, act as growth-promoting factors in some situations, and modify the way that sugars are metabolized. The receptors that mediate these actions have not yet been identified, nor have the intracellular mechanisms that they activate.

Dopamine consumed in food cannot act on the brain, because it cannot cross the blood–brain barrier. However, there are also a variety of plants that contain L-DOPA, the metabolic precursor of dopamine. The highest concentrations are found in the leaves and bean pods of plants of the genus Mucuna, especially in Mucuna pruriens (velvet beans), which have been used as a source for L-DOPA as a drug. Another plant containing substantial amounts of L-DOPA is Vicia faba, the plant that produces fava beans (also known as "broad beans"). The level of L-DOPA in the beans, however, is much lower than in the pod shells and other parts of the plant. The seeds of Cassia and Bauhinia trees also contain substantial amounts of L-DOPA.

In a species of marine green algae Ulvaria obscura, a major component of some algal blooms, dopamine is present in very high concentrations, estimated at 4.4% of dry weight. There is evidence that this dopamine functions as an anti-herbivore defense, reducing consumption by snails and isopods.

As a precursor for melanin

dopamine-melanin

Melanins are a family of dark-pigmented substances found in a wide range of organisms. The melanin that darkens human skin is not of this type: it is synthesized by a pathway that uses L-DOPA as a precursor but not dopamine.

Dopamine-derived melanin probably appears in at least some other biological systems as well. Some of the dopamine in plants is likely to be used as a precursor for dopamine-melanin. The complex patterns that appear on butterfly wings, as well as black-and-white stripes on the bodies of insect larvae, are also thought to be caused by spatially structured accumulations of dopamine-melanin.

History and development

Main article: History of catecholamine research

Dopamine was first synthesized in 1910 by George Barger and James Ewens at Wellcome Laboratories in London, England and first identified in the human brain by Katharine Montagu in 1957. It was named dopamine because it is a monoamine whose precursor in the Barger-Ewens synthesis is 3,4-dihydroxyphenylalanine (levodopa or L-DOPA). Dopamine's function as a neurotransmitter was first recognized in 1958 by Arvid Carlsson and Nils-Åke Hillarp at the Laboratory for Chemical Pharmacology of the National Heart Institute of Sweden. Carlsson was awarded the 2000 Nobel Prize in Physiology or Medicine for showing that dopamine is not only a precursor of norepinephrine (noradrenaline) and epinephrine (adrenaline), but is also itself a neurotransmitter.

Polydopamine

Research motivated by adhesive polyphenolic proteins in mussels led to the discovery in 2007 that a wide variety of materials, if placed in a solution of dopamine at slightly basic pH, will become coated with a layer of polymerized dopamine, often referred to as polydopamine. This polymerized dopamine forms by a spontaneous oxidation reaction, and is formally a type of melanin. Furthermore, dopamine self-polymerization can be used to modulate the mechanical properties of peptide-based gels. Synthesis of polydopamine usually involves reaction of dopamine hydrochloride with Tris as a base in water. The structure of polydopamine is unknown.

Polydopamine coatings can form on objects ranging in size from nanoparticles to large surfaces. Polydopamine layers have chemical properties that have the potential to be extremely useful, and numerous studies have examined their possible applications. At the simplest level, they can be used for protection against damage by light, or to form capsules for drug delivery. At a more sophisticated level, their adhesive properties may make them useful as substrates for biosensors or other biologically active macromolecules.

References

References

1. (2013). "CSD Entry TIRZAX: 5-(2-Ammonioethyl)-2-hydroxyphenolate, Dopamine". [[Cambridge Crystallographic Data Centre]].
2. (2013). "Tautomeric and ionisation forms of dopamine and tyramine in the solid state". [[Journal of Molecular Structure.
3. (April 2007). "The debate over dopamine's role in reward: the case for incentive salience". Psychopharmacology.
4. (January 2020). "Dopamine and Addiction". Annual Review of Psychology.
5. (October 2013). "Parceling human accumbens into putative core and shell dissociates encoding of values for reward and pain". The Journal of Neuroscience.
6. (January 2015). "A role for phasic dopamine release within the nucleus accumbens in encoding aversion: a review of the neurochemical literature". ACS Chemical Neuroscience.
7. (June 2012). "Prefrontal/accumbal catecholamine system processes high motivational salience". Front. Behav. Neurosci..
8. (2008). "The myth of the chemical cure. A critique of psychiatric drug treatment". Palgrave MacMillan.
9. (September 2009). "Evaluating dopamine reward pathway in ADHD: clinical implications". JAMA.
10. "Dopamine infusion".
11. "Shock and Hypotension in the Newborn Medication: Alpha/Beta Adrenergic Agonists, Vasodilators, Inotropic agents, Volume Expanders, Antibiotics, Other".
12. "Dopamine". PubChem.
13. "Catecholamine".
14. "Phenylethylamine". ChemicalLand21.com.
15. (1982). "Dopamine Hydrochloride". Analytical Profiles of Drug Substances.
16. "Specification Sheet".
17. (July 2016). "EC 1.14.16.2 – Tyrosine 3-monooxygenase (Homo sapiens)". Technische Universität Braunschweig.
18. (July 2016). "EC 4.1.1.28 – Aromatic-L-amino-acid decarboxylase (Homo sapiens)". Technische Universität Braunschweig.
19. (2013). "Biochemistry of Biogenic Amines". Springer.
20. (September 2004). "Catecholamine metabolism: a contemporary view with implications for physiology and medicine". Pharmacological Reviews.
21. (December 2018). "Parkinson's Disease: Pathogenesis and Clinical Aspects [Internet].". Codon Publications.
22. (1992). "Homovanillic acid measurement in clinical research: a review of methodology". Schizophrenia Bulletin.
23. (1995). "Assessment of the central dopaminergic index of plasma HVA in schizophrenia". Schizophrenia Bulletin.
24. (February 2000). "Intraneuronal dopamine-quinone synthesis: a review". Neurotoxicity Research.
25. (June 2008). "Dopaminergic neuron-specific oxidative stress caused by dopamine itself". Acta Medica Okayama.
26. "Dopamine: Biological activity". International Union of Basic and Clinical Pharmacology.
27. (February 2016). ""TAARgeting Addiction" – The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference". Drug and Alcohol Dependence.
28. (2009). "The Dopamine Receptors". Springer.
29. (2009). "The Dopamine Receptors". Springer.
30. (February 2006). "Targeting exocytosis: ins and outs of the modulation of quantal dopamine release". CNS & Neurological Disorders Drug Targets.
31. (January 2003). "Plasma membrane monoamine transporters: structure, regulation and function". Nature Reviews. Neuroscience.
32. (December 2011). "Dopamine release in the basal ganglia". Neuroscience.
33. (2007). "Multiple dopamine functions at different time courses". Annual Review of Neuroscience.
34. (1964). "Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons". Acta Physiologica Scandinavica. Supplementum.
35. (May 2007). "Dopamine neuron systems in the brain: an update". Trends in Neurosciences.
36. (September 2004). "Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance". The American Journal of Medicine.
37. (September 2009). "Dopamine is necessary for cue-dependent fear conditioning". The Journal of Neuroscience.
38. (April 2020). "A VTA to basal amygdala dopamine projection contributes to signal salient somatosensory events during fear learning". The Journal of Neuroscience.
39. (November 2018). "Dopamine Neurons Reflect the Uncertainty in Fear Generalization". Neuron.
40. (June 2006). "Dopamine and the spinal cord in restless legs syndrome: does spinal cord physiology reveal a basis for augmentation?". Sleep Medicine Reviews.
41. (December 2001). "Dopamine as a prolactin (PRL) inhibitor". Endocrine Reviews.
42. (January 2004). "Dopamine and retinal function". Documenta Ophthalmologica. Advances in Ophthalmology.
43. (September 2010). "What do the basal ganglia do? A modeling perspective". Biological Cybernetics.
44. (January 2015). "The nucleus accumbens: an interface between cognition, emotion, and action". Annual Review of Psychology.
45. (2015). "Hierarchical control of goal-directed action in the cortical–basal ganglia network". Current Opinion in Behavioral Sciences.
46. (April 2008). "The neuropharmacology of impulsive behaviour". Trends in Pharmacological Sciences.
47. (1993). "The neural basis of drug craving: an incentive-sensitization theory of addiction". Brain Research. Brain Research Reviews.
48. (July 2015). "Neuronal Reward and Decision Signals: From Theories to Data". Physiological Reviews.
49. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
50. (December 2010). "Dopamine in motivational control: rewarding, aversive, and alerting". Neuron.
51. (August 2015). "The ins and outs of the striatum: Role in drug addiction". Neuroscience.
52. (August 2015). "Differential Dopamine Release Dynamics in the Nucleus Accumbens Core and Shell Reveal Complementary Signals for Error Prediction and Incentive Motivation". The Journal of Neuroscience.
53. (May 2015). "Pleasure systems in the brain". Neuron.
54. (October 2008). "Dopamine and reward: the anhedonia hypothesis 30 years on". Neurotoxicity Research.
55. (2007). "Dopamine, learning and reward-seeking behavior". Acta Neurobiol Exp.
56. (November 2007). "Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex". Brain Research Reviews.
57. (2019). "Dopamine modulates the reward experiences elicited by music". Proceedings of the National Academy of Sciences of the United States of America.
58. (May 1998). "Evidence for striatal dopamine release during a video game". Nature.
59. (2019). "The Association Between Video Gaming and Psychological Functioning". Frontiers in Psychology.
60. (January 1998). "Dopamine receptors: from structure to function". Physiological Reviews.
61. (June 2011). "The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders". Current Neuropharmacology.
62. (May 2010). "The immunoregulatory role of dopamine: an update". Brain, Behavior, and Immunity.
63. (February 2003). "Renal dopamine receptors and hypertension". Experimental Biology and Medicine.
64. (May 2015). "Renal dopaminergic system: Pathophysiological implications and clinical perspectives". World Journal of Nephrology.
65. (September 2001). "Theodore Cooper Lecture: Renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure". Hypertension.
66. (December 2010). "Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let's seek the balance". Endocrinology.
67. (October 2013). "WHO Model List of Essential Medicines".
68. (2003). "Pharmacology Review Developmentally Regulated Cardiovascular, Renal, and Neuroendocrine Effects of Dopamine". NeoReviews.
69. (1989). "Dopamine and dobutamine in pediatric therapy". Pharmacotherapy.
70. (2009). "Pharmacology for Health Professionals". Elsevier Australia.
71. (March 2010). "Comparison of dopamine and norepinephrine in the treatment of shock". The New England Journal of Medicine.
72. (2006). "Low-dose dopamine in the intensive care unit". Seminars in Dialysis.
73. "Dopamine".
74. (2013). "Clinical Cardiology: Current Practice Guidelines". OUP Oxford.
75. (May 2004). "Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the beta2 adrenergic receptor". Molecular Pharmacology.
76. (2004). "Sax's Dangerous Properties of Industrial Materials". Wiley & Sons.
77. (2011). "Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy". Lippincott Williams & Wilkins.
78. (2009). "Handbook of the neuroscience of aging". Elsevier/Academic Press.
79. (July 2006). "Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with L-[beta-11C]DOPA". Life Sciences.
80. (2000). "Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain". Neurobiology of Aging.
81. (September 1998). "Age-dependent decline of dopamine D1 receptors in human brain: a PET study". Synapse.
82. (December 1984). "Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain". Science.
83. (1998). "Handbook of the aging brain". Academic Press.
84. (12 March 2015). "The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders". Frontiers in Neurology.
85. (April 2016). "Multiple sclerosis: Repurposing dopaminergic drugs for MS—the evidence mounts". Nature Reviews. Neurology.
86. (April 2008). "Parkinson's disease: clinical features and diagnosis". Journal of Neurology, Neurosurgery, and Psychiatry.
87. (2007). "Parkinson's disease and movement disorders". Lippincott Williams & Wilkins.
88. (April 2007). "Parkinsonism: a review-of-systems approach to diagnosis". Seminars in Neurology.
89. (December 2011). "Natural rewards, neuroplasticity, and non-drug addictions". Neuropharmacology.
90. (November 2010). "Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders". Journal of Neurology.
91. (August 2017). "Cocaine Potency at the Dopamine Transporter Tracks Discrete Motivational States During Cocaine Self-Administration". Neuropsychopharmacology.
92. (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". CNS Drugs.
93. (2009). "Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs a comprehensive review on their mode of action, treatment of abuse and intoxication". Springer.
94. (January 2011). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry.
95. (2010). "Ghodse's Drugs and Addictive Behaviour: A Guide to Treatment". Cambridge University Press.
96. "Quillivant XR – methylphenidate hydrochloride suspension, extended release".
97. (September 2013). "Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges". Attention Deficit and Hyperactivity Disorders.
98. (August 2013). "The clinical neurobiology of drug craving". Current Opinion in Neurobiology.
99. (January 2014). "Addiction science: Uncovering neurobiological complexity". Neuropharmacology.
100. (September 2011). "The organization of the human cerebral cortex estimated by intrinsic functional connectivity". Journal of Neurophysiology.
101. "Goodman and Gilman's The Pharmacological Basis of Therapeutics". McGraw Hill.
102. (May 2009). "The dopamine hypothesis of schizophrenia: version III—the final common pathway". Schizophrenia Bulletin.
103. (2006). "Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia". CNS Drugs.
104. (2004). "The Creation of Psychopharmacology". Harvard University Press.
105. (2018). "Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate.". CNS Spectr.
106. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
107. (June 2012). "Role of dopamine receptors in ADHD: a systematic meta-analysis". Molecular Neurobiology.
108. (June 2011). "Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder". Biological Psychiatry.
109. (June 2015). "The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex". Biological Psychiatry.
110. (June 2015). "Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis". Journal of Cognitive Neuroscience.
111. (May 2008). "Role of central dopamine in pain and analgesia". Expert Review of Neurotherapeutics.
112. (March 2004). "Practical selection of antiemetics". American Family Physician.
113. (2014). "Pharmacological treatment of Parkinson disease: a review". JAMA.
114. (March 2022). "Dopamine and fear memory formation in the human amygdala". Molecular Psychiatry.
115. (March 2024). "65 years of research on dopamine's role in classical fear conditioning and extinction: A systematic review". The European Journal of Neuroscience.
116. (2010). "Microbial Endocrinology". Springer.
117. (July 2004). "Evolution of cell-cell signaling in animals: did late horizontal gene transfer from bacteria have a role?". Trends in Genetics.
118. (2004). "Isolation of Araguspongine M, a new stereoisomer of an Araguspongine/Xestospongin alkaloid, and dopamine from the marine sponge ''Neopetrosia exigua'' collected in Palau". Marine Drugs.
119. (January 2007). "Cnidarian chemical neurotransmission, an updated overview". Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology.
120. (January 1967). "Occurrence of dopamine and noradrenaline in the nervous tissue of some invertebrate species". British Journal of Pharmacology and Chemotherapy.
121. (August 2007). "Dopamine mediates context-dependent modulation of sensory plasticity in C. elegans". Neuron.
122. (2010). "The roles of dopamine and related compounds in reward-seeking behavior across animal phyla". Frontiers in Behavioral Neuroscience.
123. (October 2004). "A possible role of midbrain dopamine neurons in short- and long-term adaptation of saccades to position-reward mapping". Journal of Neurophysiology.
124. (January 2015). "Distinct dopamine neurons mediate reward signals for short- and long-term memories". Proceedings of the National Academy of Sciences of the United States of America.
125. (June 2013). "Reinforcement signalling in Drosophila; dopamine does it all after all". Current Opinion in Neurobiology.
126. (August 1994). "Quantification of L-Dopa and Dopamine in Squid Ink: Implications for Chemoreception". The Biological Bulletin.
127. (2007). "Catecholamines are active compounds in plants". Plant Science.
128. (2003). "L-DOPA bearing plants". Natural Product Radiance.
129. (1993). "Occurrence of L-DOPA and dopamine in plants and cell cultures of ''Mucuna pruriens'' and effects of 2, 4-d and NaCl on these compounds". Plant Cell, Tissue and Organ Culture.
130. (1974). "Distribution of l-dopa and related amino acids in Vicia". Phytochemistry.
131. (June 2006). "Dopamine functions as an antiherbivore defense in the temperate green alga Ulvaria obscura". Oecologia.
132. (October 2009). "Current challenges in understanding melanogenesis: bridging chemistry, biological control, morphology, and function". Pigment Cell & Melanoma Research.
133. (1967). "Melanins from DOPA-containing plants". Phytochemistry.
134. (June 2002). "The genetics and evo-devo of butterfly wing patterns". Nature Reviews. Genetics.
135. (2008). "The history of dopamine and levodopa in the treatment of Parkinson's disease". Movement Disorders.
136. (January 2001). "Carlsson and the discovery of dopamine". Trends in Pharmacological Sciences.
137. (2003). "Better Than Prozac". Oxford University Press.
138. (October 2007). "Mussel-inspired surface chemistry for multifunctional coatings". Science.
139. (2013). "Perspectives on poly(dopamine)". Chemical Science.
140. (December 2011). "Polydopamine—a nature-inspired polymer coating for biomedical science". Nanoscale.
141. (March 2021). "Dopamine Self-Polymerization as a Simple and Powerful Tool to Modulate the Viscoelastic Mechanical Properties of Peptide-Based Gels". Molecules.